Mendelian susceptibility to poorly virulent mycobacteria such as bacillus Calmette-Guerin (BCG) and environmental nontuberculous mycobacteria is a clinically heterogeneous syndrome. The clinical features of affected children cover a continuous spectrum from disseminated lethal bacillus Calmette-Guerin infection to local recurrent nontuberculous mycobacterial infection. Different types of mutations in four genes (IFNGR1, IFNGR2, IL12B, IL12RB1) have revealed both allelic and nonallelic heterogeneity and result in eight different disorders whose common pathogenic pathway is impaired interferon gamma (IFN␥) mediated immunity. The severity of the clinical phenotype depends on the genotype. Complete IL-12 p40 and IL-12 receptor ␤1 deficiencies and partial IFN␥ receptor 1 (IFN␥R1) and IFN␥R2 deficiencies generally lead to curable infections at various ages, and antibiotics supplemented with IFN␥ if required are likely to be effective. Complete IFN␥R1 and IFN␥R2 deficiencies predispose to overwhelming infection in early childhood, which may respond to antibiotics but relapse when antibiotics are discontinued. Rapid discrimination between complete IFN␥R1 and IFN␥R2 deficiency and other defects, therefore, is an important diagnostic step for planning clinical management. BCG vaccines and environmental NTM are known to cause severe diseases in immunocompromised children. It is less well known that otherwise healthy children may also be affected (1) (2) (3) (4) . Unlike children with classic immunodeficiency, who suffer from other clinical diseases caused by various viruses, bacteria, fungi, and protozoa, children with severe idiopathic BCG and NTM infection generally do not have other associated symptomatic infections apart from salmonellosis, which occurs in less than half the cases. Clinical diseases caused by cytomegalovirus, herpes simplex virus, Listeria monocytogenes, and Histoplasma capsulatum have each been found in only one patient (5) (6) (7) (8) (9) .
Although these children are not vulnerable to a wide range of infectious agents, the syndrome was thought to be due to impaired immunity specifically altering host defenses against mycobacteria. Parental consanguinity and familial forms are frequent, and the syndrome is often described as Mendelian susceptibility to mycobacterial infection (MIM 209950) (10) . The clinical syndrome is rare, and its inheritance may differ between kindreds. Although autosomal recessive in most cases, autosomal dominant (8, 9) and X-linked recessive inheritance have been reported (3, 11) .
Cases from various ethnic groups and geographic regions have been reported. The prevalence of the syndrome is difficult to determine, as it includes a continuous spectrum from disseminated lethal BCG infection to local recurrent NTM infection. Disseminated forms themselves are heterogeneous, and clinical features correlate with the type of histopathologic lesions present (12) , so that children with lepromatous-like BCG granulomas generally die of overwhelming infection, whereas children with tuberculoid granulomas have a favorable prognosis. The prevalence of idiopathic disseminated BCG infection in France has been estimated to be at least 0.59 cases per million children vaccinated (1) .
Mutations have been found in four genes (IFNGR1, IFNGR2, IL12B, IL12RB1). Different types of mutations result in eight different disorders whose common pathogenic mechanism is impaired IFN␥-mediated immunity. However, these defects account for only a minority of patients. IL-12, a heterodimeric cytokine, is secreted by phagocytes and dendritic cells upon infection with mycobacteria. IL-12 is composed of two subunits, p40 and p35, that together form the biologically active p70 heterodimer. IL-12R consist of two chains, IL-12R␤1 and IL-12R␤2, that are selectively expressed on natural killer and activated T cells. Binding of IL-12 to these receptors leads to STAT4 activation, followed by the induction of IFN␥ (Figs. 1 and 2) (13, 14) . IL-12p40 and IL-12R␤1 deficiencies, thus, result in impaired IFN␥ production.
IFN␥, a homodimer with pleiotropic effects, is one of the principal macrophage-activating cytokines. IFN␥ acts through a ubiquitous cell-surface receptor composed of two chains, IFN␥R1, the ligand-binding chain, and IFN␥R2, which is required for signal transduction. Upon ligand binding, STAT1, an essential component of the IFN␥ signaling pathway, is phosphorylated and translocates to the nucleus as a homodimer where it acts as a transcriptional activator, interacting with the promoter region of IFN␥-inducible genes ( Fig. 3) (15, 16) . Various types of IFN␥R1 and IFN␥R2 defects impair cellular responses to IFN␥ (see Figs. 4 and 5 and text below). These disorders generally manifest in childhood, although they may become apparent during adulthood. The rarity and heterogeneity of the syndrome make accurate diagnosis and treatment difficult for pediatricians, especially as the clinical boundaries are poorly defined and most patients lack a clear genetic etiology. In this article, we briefly review the known inheritable disorders, emphasizing their molecular pathogenesis, clinical features, diagnosis, and management. Reviews of other aspects of the syndrome can be found elsewhere (17) (18) (19) .
GENETICS AND IMMUNOLOGY
A child with a homozygous recessive deletion in the p40 subunit of IL-12, which leads to complete IL-12p40 deficiency, has been reported (20) . Recently, we identified other families with IL-12p40 deficiency, showing that this disorder is not limited to a single kindred (Picard C, in preparation). Patients with other IL-12 regulation defects and undefined X-recessive genetic defects in trans have been reported (3) . Due to a lack of stimulation through IL-12, these patients produce less IFN␥, which may be partially corrected in a dose-dependent manner with exogenous recombinant IL-12. This confirms that the impairment of IFN␥ production is not a primary event but a consequence of inherited IL-12 deficiency. In other patients, recessive mutations preclude expression of the IL-12R␤1 chain on the surface of natural killer and T cells (21) (22) (23) (24) (25) (26) . To date, no partial defect of IL-12 or IL-12R has been identified.
Complete IFN␥R1 deficiency (Fig. 4) may be due to recessive mutations that either preclude surface expression of the receptor ligand-binding chain (6, 7, (27) (28) (29) (30) or result in normal surface expression of IFN␥R1 chains that do not bind IFN␥ (31, 32) . One child has been reported to have complete IFN␥R2 deficiency (Fig. 5) due to a homozygous recessive deletion in the coding region of the gene, resulting in a premature stop codon in the extracellular domain (33) . Cellsurface expression of IFN␥R1 was normal, but no IFN␥R2 expression was detected. Other patients have been diagnosed with complete IFN␥R2 deficiency, showing that this disorder is not limited to a single kindred (34) .
A homozygous recessive mutation, which probably reduces the affinity of IFN␥R1 for its ligand, has been identified in two siblings (35) . Cell-surface expression of the receptor ligandbinding chain was normal. Another patient had a homozygous recessive mutation in the IFN␥R2 chain with impaired responses to IFN␥ and normal surface expression (36) . Both recessive defects lead to partial, as opposed to complete, IFN␥R deficiency (Figs. 4 and 5 ).
An autosomal dominant form of partial IFN␥R1 deficiency was found in 18 patients of 12 unrelated kindreds (8, 9) . The mutant allele encodes an intracellular truncated receptor that binds IFN␥ with normal affinity but cannot transduce IFN␥-triggered signals and accumulates on the cell surface. The combination of normal IFN␥ binding, impaired signaling, and the accumulation of the receptor on the cell surface (five to 10 times the normal number of receptors) accounts for the dominant negative effect of the truncated mutant IFN␥R1 molecules. Most IFN␥R1 molecules are nonfunctional, but the few wild-type dimers that do form cause the defect to be partial rather than complete (Figs. 4 and 5 ).
HISTOLOGIC AND CLINICAL FEATURES
A multicenter survey is underway to define precisely the clinical and histologic phenotypes of patients with the syndrome and each of the underlying genetic defects. In all patients known to date, mycobacterial infection is the principal clinical presentation, and none has clinical atopy or serologic Generally, patients with IL-12 and IL-12R deficiencies have mild symptoms with delayed but good granuloma formation in response to BCG vaccination (20) and impaired granuloma formation after NTM infection. The child with complete IL12p40 deficiency presented with curable BCG and Salmonella enteritidis infections (20) , and the patients with IL-12 regulation deficiency had Mycobacterium avium infections (3). The patients with complete IL-12R␤1 deficiencies presented with curable BCG infection upon vaccination and NTM infections after the age of 3 y, with these infections not occurring until adulthood in two. In one patient, the infection was fatal. The milder clinical phenotype in comparison to children with complete IFN␥R deficiencies is probably due to residual, albeit low, IL-12-independent IFN␥-mediated immunity.
Surprisingly, the affected sister of one of the IL-12R␤1-deficient patients with BCG infection was resistant to three inoculations of BCG but developed abdominal tuberculosis at the age of 18 y. The two siblings, thus, had the same genotype but different clinical phenotypes (25) . This demonstrates phenotypic heterogeneity for a given genotype in IL-12R␤1 deficiency. Moreover, it raises the question as to whether other children with severe tuberculosis may have IL-12R␤1 deficiencies.
The clinical phenotype of patients with partial IFN␥R deficiency is generally mild like that in IL-12R deficiency. One patient with partial recessive IFN␥R1 deficiency presented with clinical BCG and Salmonella enteritidis infections, and the other patient who was not vaccinated had symptomatic tuberculosis. In all tissue biopsies, mature granulomas were seen. The patient with partial recessive IFN␥R2 deficiency had a history of BCG and Mycobacterium abscessus infections. In the dominant forms of partial IFN␥R deficiency, the clinical phenotype is mild even though the course of infection appears to be somewhat more severe than in partial recessive IFN␥R deficiency (8, 9) .
Patients with complete IFN␥R1 or IFN␥R2 deficiency suffer from a severe form of the syndrome, with BCG infection after immunization and early onset NTM infection (often before 3 y of age). Lethal infection due to Mycobacterium smegmatis, one of the least virulent mycobacteria that had never been previously identified as a cause of disseminated clinical disease, has occurred once (30) . Other rapidly growing mycobacterial species such as M. fortuitum but also M. avium, Salmonella, and Listeria monocytogene infections have been reported. Severe diseases caused by viruses, such as CMV and HSV, have been diagnosed each in one child (5) . No other opportunistic infections were observed, and common childhood infections followed a normal course. Lepromatous-like lesions, particularly in response to BCG vaccination, were observed and are suggestive of complete IFN␥R1 or IFN␥R2 deficiency.
There is a correlation between genotype and cellular and clinical phenotype for patients with IFN␥R deficiencies. Thus, IFN␥-mediated cell activation is a genetically controlled continuous quantitative trait that determines the outcome of mycobacterial infection in men (38) . In contrast, the clinical phenotype of patients with IL-12 or IL-12R gene defect is more heterogeneous between and within families.
DIAGNOSIS
Rapid diagnosis of complete IFN␥R deficiency is essential for the planning of clinical management and can be made by determining serum IFN␥ levels by ELISA (34) . High IFN␥ levels suggest complete IFN␥R deficiency, whereas low or undetectable levels indicate IL-12, IL-12R, partial IFN␥R, or undetermined defects (6). More specialized assays are necessary to determine the exact molecular etiology of the disease in each patient.
IL-12p40 deficiency can be diagnosed by ELISA, with the levels of IL-12p40, IL-12p70, and IFN␥ secretion of stimulated peripheral blood mononuclear cells being low. IL-12R␤1 deficiency results in low levels of IFN␥ production, and FACS analysis cannot detect the IL-12R␤1 chain on activated T cells. Gene sequencing and, depending on the mutation, in vitro gene transfer are needed to confirm the diagnosis.
Several functional studies have assessed the cellular responses to recombinant IFN␥. ELISA can be used to quantify tumor necrosis factor-␣ (TNF-␣) production by blood cells in response to lipopolysaccharide alone and lipopolysaccharide 125 I-IFN␥ binding to the cells was shown (ϩ) or is expected to be normal (ϩ?). The mutations, therefore, define two types of AR IFN␥R2 deficiency that differ in IFN␥R2 cell-surface expression (ϩ, normal; Ϫ, lack of expression) and in the type of signaling defect (partial or complete).
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IMPAIRED INTERFERON GAMMA-MEDIATED IMMUNITY plus IFN␥ (4, 28) . STAT1 nuclear translocation can be determined by electrophoretic mobility shift assay, using cultured EBV-transformed B cells (35) . Alternatively, it is possible to detect intracellular phosphorylated STAT1 by flow cytometry (39) . HLA-DR surface induction can be detected in SV40-transformed fibroblasts by flow cytometry with specific antibodies (27) .
Cells from patients with complete IFN␥R deficiency do not respond to IFN␥ even at high concentrations (10 5 IU/mL), whereas cells from patients with partial deficiencies respond to high but not to low concentrations of IFN␥. In addition, over-expression of the IFN␥R1 chain in the autosomal dominant form facilitates rapid diagnosis of this form of partial IFN␥R1 deficiency by FACS analysis (8, 9) . Here, too, gene sequencing and, depending on the mutation, in vitro gene transfer provide the molecular diagnosis of the patients.
TREATMENT AND PROGNOSIS
For all patients, appropriate antibiotic therapy based on the sensitivity of the mycobacterial species identified is crucial. However, for initial empirical therapy, a history of BCG vaccination is important, and unvaccinated children should be considered affected by NTM, although tuberculosis should be considered in some cases. Antimycobacterial therapy may have to be continued for extended periods, and supplementary measures such as the drainage of pus and attention to nutrition and growth are important. Occasionally, splenectomy (40) or surgical resection of refractory infectious sites such as abdominal lymph nodes may be required. BCG immunization is contraindicated, and it is prudent to avoid other live vaccines.
Patients with IL-12, IL-12R, and partial IFN␥R defects usually respond well to antibiotic treatment, and, in those who do not respond well, additional IFN␥ therapy has been shown to be effective. Experience shows that this option should be considered individually for each patient. An initial dose of 30 to 50 g/m 2 given s.c. three times a week should be adapted according to clinical and in vitro responses. Doses as high as 500 g/m 2 may be necessary (18) . The molecular diagnosis of complete IFN␥R1 and IFN␥R2 deficiency has important therapeutic implications, as mycobacterial disease in patients with such deficiencies is generally overwhelming and may be refractory to antibiotic treatment. Although some patients respond initially to antibiotics, a full remission is rarely achieved and relapses invariably occur if antibiotics are discontinued. Bone marrow transplantation probably remains the treatment of choice, because IFN␥ is ineffective in the absence of specific functional receptors. However, transplantation has proved difficult in several patients (unpublished observations). Gene therapy should be developed in the future for the treatment of complete IFN␥R deficiencies, but further research is required to make this possibility a reality.
CONCLUSIONS
Mendelian susceptibility to mycobacterial infection is a rare and heterogeneous syndrome of childhood that is probably underdiagnosed. The clinical features of affected children range from disseminated lethal BCG infection to local and recurrent NTM infection. Various mutations in IFNGR1, IFNGR2, IL12B, and IL12RB1 define eight genetically different disorders. These disorders are immunologically related, as impaired IFN␥-mediated immunity is the common pathogenic mechanism underlying mycobacterial infection in all patients. The severity of the clinical phenotype depends on the genotype. Complete IL-12p40 and IL-12R␤1 deficiencies and partial IFN␥R1 and IFN␥R2 deficiencies generally predispose the patient to curable infections at various ages. Antibiotics supplemented with IFN␥ if required are likely to be effective, and bone marrow transplantation is, therefore, not indicated. Complete IFN␥R1 and IFN␥R2 deficiencies predispose the patient to overwhelming infection in early childhood. The response to antibiotics is poor and IFN␥ treatment ineffective, which probably makes bone marrow transplantation the treatment of choice. There is a genotype-phenotype correlation for IFN␥R defects unlike for IL-12 and IL-12R defects. Rapid discrimination between complete IFN␥R deficiency and other defects by ELISA determination of serum IFN␥ levels is an important diagnostic step for planning clinical management. However, diagnosis of the molecular defect remains difficult, as the syndrome is heterogeneous and few standardized assays are available. Tests to detect IFN␥ and IL-12 cytokines and their receptors, followed by functional assays, gene sequencing, and in vitro gene transfer, provide a definite diagnosis in only a minority of cases. The treatment of other patients with unknown genetic defects remains empirical. Future research will focus on the search for other underlying genetic defects to provide a rational basis for the management of patients with mycobacterial disease.
